ChemioCare USA welcomes Roy Waldron to its Board of Directors

– USA, NY –  ChemioCare USA Inc., a platform company focused on proprietary transdermal delivery, announced today the appointment of Roy F. Waldron to its Board of Directors, effective immediately.

“We are pleased to welcome Roy to our Board of Directors. His experience in developing, executing, and defending Intellectual property strategies at Pfizer will be invaluable as we continue to build our company,” said Pedro Lichtinger, Chairman and CEO. “We expect to continue to strengthen the IP portfolio for our PETT platform and for each unique patch as they progress in their development process and generate novel data and findings.”

About Roy Waldron

Mr. Waldron brings over 20 years of legal and intellectual property experience to ChemioCare. He recently retired from his role as Senior Vice President‚ Associate General Counsel and Chief Intellectual Property Counsel at Pfizer. There, he led global teams of Pfizer attorneys and professionals in procuring patents‚ and worked closely with R&D‚ Business Development and Pfizer Business Units to develop and strengthen intellectual property strategies for development and acquisition targets. He holds a JD from New York University Law School‚ a PhD from Yale and a BA from Dartmouth College.

Roy added, “As a firm believer that innovation is absolutely fundamental to delivering better healthcare to patients, I am thrilled to be part of a team prioritizing inventive technologies to solve longstanding drug delivery challenges.”

About ChemioCare

ChemioCare is a biotechnology company focused on improving the profiles of medicines through its proprietary permeation enhanced transdermal technology. The Company’s platform technology uniquely combines high flux and sustained release into a matrix drug in an adhesive patch. ChemioCare has three patches in development for cancer and cancer supportive care. Its lead programs are expected to enter phase 3 pivotal studies in late 2019. Each product leverages the 505(b)2 regulatory path and is aiming at establishing improved efficacy, a new indication, and reduced or eliminated side effects from the originator’s products.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>